Pixatimod sodium

Description: Pixatimod, aslo known as PG-545, is a synthetic sugar modified heparan sulfate mimetic and agonist of toll-like receptor 9 (TLR9), with potential immunostimulating, antineoplastic and anti-viral activities. Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 Interaction. Pixatimod blocks a number of pro-cancerous processes including cell proliferation, invasion, metastasis, angiogenesis and epithelial-mesenchymal transition. These activities have translated into potent activity using a range of different mouse cancer models, including approximately 30 xenograft and 20 syngeneic models. Pixatimod has been tested in combination with a number of approved anti-cancer drugs demonstrating its clinical potential, including with gemcitabine, paclitaxel, sorafenib, platinum agents and an anti-PD-1 antibody.


Cat. No.: EX-A9092A	Purity: >98%

	Chemical structure of Pixatimod sodium

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock	Quantity	Order
1g	get quote	Inquire

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	1144492-69-2
Purity	>98%
Formula	C51H75Na13O60S13
Mol Weight	2363.817

Reference:	1: Lemech C, Dredge K, Bampton D, Hammond E, Clouston A, Waterhouse NJ, Stanley AC, Leveque-El Mouttie L, Chojnowski GM, Haydon A, Pavlakis N, Burge M, Brown MP, Goldstein D. Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors. J Immunother Cancer. 2023 Jan;11(1):e006136. doi: 10.1136/jitc-2022-006136. PMID: 36634920; PMCID: PMC9843174. 2: Guimond SE, Mycroft-West CJ, Gandhi NS, Tree JA, Le TT, Spalluto CM, Humbert MV, Buttigieg KR, Coombes N, Elmore MJ, Wand M, Nyström K, Said J, Setoh YX, Amarilla AA, Modhiran N, Sng JDJ, Chhabra M, Young PR, Rawle DJ, Lima MA, Yates EA, Karlsson R, Miller RL, Chen YH, Bagdonaite I, Yang Z, Stewart J, Nguyen D, Laidlaw S, Hammond E, Dredge K, Wilkinson TMA, Watterson D, Khromykh AA, Suhrbier A, Carroll MW, Trybala E, Bergström T, Ferro V, Skidmore MA, Turnbull JE. Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS- CoV-2 by Disrupting the Spike-ACE2 Interaction. ACS Cent Sci. 2022 May 25;8(5):527-545. doi: 10.1021/acscentsci.1c01293. Epub 2022 Mar 29. PMID: 35647275; PMCID: PMC9136977. 3: Chhabra M, Wilson JC, Wu L, Davies GJ, Gandhi NS, Ferro V. Structural Insights into Pixatimod (PG545) Inhibition of Heparanase, a Key Enzyme in Cancer and Viral Infections. Chemistry. 2022 Feb 19;28(11):e202104222. doi: 10.1002/chem.202104222. Epub 2022 Jan 31. PMID: 34981584; PMCID: PMC9303737. 4: Chhabra M, Wimmer N, He QQ, Ferro V. Development of Improved Synthetic Routes to Pixatimod (PG545), a Sulfated Oligosaccharide-Steroid Conjugate. Bioconjug Chem. 2021 Nov 17;32(11):2420-2431. doi: 10.1021/acs.bioconjchem.1c00453. Epub 2021 Oct 15. PMID: 34652896. 5: Kinaneh S, Khamaysi I, Karram T, Hamoud S. Heparanase as a potential player in SARS-CoV-2 infection and induced coagulopathy. Biosci Rep. 2021 Jul 30;41(7):BSR20210290. doi: 10.1042/BSR20210290. PMID: 34132790; PMCID: PMC8255537. 6: Hammond E, Dredge K. Heparanase Inhibition by Pixatimod (PG545): Basic Aspects and Future Perspectives. Adv Exp Med Biol. 2020;1221:539-565. doi: 10.1007/978-3-030-34521-1_22. PMID: 32274726. 7: Chhabra M, Ferro V. PI-88 and Related Heparan Sulfate Mimetics. Adv Exp Med Biol. 2020;1221:473-491. doi: 10.1007/978-3-030-34521-1_19. PMID: 32274723. 8: Bendersky V, Yang Y, Brennan TV. Immunomodulatory Activities of the Heparan Sulfate Mimetic PG545. Adv Exp Med Biol. 2020;1221:461-470. doi: 10.1007/978-3-030-34521-1_18. PMID: 32274722. 9: Koliesnik IO, Kuipers HF, Medina CO, Zihsler S, Liu D, Van Belleghem JD, Bollyky PL. The Heparan Sulfate Mimetic PG545 Modulates T Cell Responses and Prevents Delayed-Type Hypersensitivity. Front Immunol. 2020 Feb 6;11:132. doi: 10.3389/fimmu.2020.00132. PMID: 32117279; PMCID: PMC7015948. 10: Hammond E, Haynes NM, Cullinane C, Brennan TV, Bampton D, Handley P, Karoli T, Lanksheer F, Lin L, Yang Y, Dredge K. Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors. J Immunother Cancer. 2018 Jun 14;6(1):54. doi: 10.1186/s40425-018-0363-5. PMID: 29898788; PMCID: PMC6000956. 11: Dredge K, Brennan TV, Hammond E, Lickliter JD, Lin L, Bampton D, Handley P, Lankesheer F, Morrish G, Yang Y, Brown MP, Millward M. A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours. Br J Cancer. 2018 Apr;118(8):1035-1041. doi: 10.1038/s41416-018-0006-0. Epub 2018 Mar 13. PMID: 29531325; PMCID: PMC5931096.
CoA	CoA of Pixatimod sodium

Smiles:	CC(CCC[C@@]([C@@]1([H])CC[C@@]2([H])[C@]([C@]3([H])CC[C@]12C)([H])CC[C@@]4([H])C[C@](O[C@@]5([H])[C@@](OS([O-])(=O)=O)([H])[C@](OS([O-])(=O)=O)([H])[C@@](O[C@]6([H])[C@@](OS([O-])(=O)=O)([H])[C@](OS([O-])(=O)=O)([H])[C@@](O[C@]7([H])[C@@](OS([O-])(=O)=O)(


		Search